ClinicalTrials.gg
CompletedNCT03268941Updated Jan 6, 2021Results posted

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

A Phase 2 interventional study of TAK-906 Maleate and Metaclopramide in Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Diabetes Mellitus by Takeda — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Takeda.

Enrollment
59th of 66
51 · median 326
Started
2017
the only one that year
Phase 2
12 of 71
none open now
Registered
71st of 71
by date

Among the 71 studies in Diabetes Mellitus by Takeda, this one is the 59th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2017, is one of 12 in phase 2, and was the 71st registered.

Diabetes Mellitus

8,292 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 71 studies in Diabetes Mellitus by Takeda is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Diabetes Mellitus by Takeda as a file.
02

Study summary

The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).

Read the detailed description

The drug being tested in this study is called TAK-906 maleate. TAK-906 maleate is being tested to treat people who have DG or IG. This study will assess the safety, tolerability, PK/PD and food effect of TAK-906 and will determine the effect of TAK-906 on gastric emptying (GE).

The study enrolled a total of 51 participants. This study will be conducted in two parts: Part 1 and Part 2. Part 1 will consist of 48 participants enrolled in 3 active treatment groups and 1 placebo group. Participants in Part 1 will be randomly assigned (by chance, like flipping a coin) to one of the 3 active treatment groups or 1 placebo group-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • TAK 906 maleate 5 mg
  • TAK 906 maleate 25 mg
  • TAK 906 maleate 100 mg
  • Placebo

All participants who will complete Part 1 of the study will be eligible for enrollment in Part 2. Part 2 consisted of 21 participants who completed Part 1 and were assigned to the 2 open-label treatment groups as follow:

  • TAK-906 maleate 25 mg Fed + TAK-906 maleate 25 mg Fasted: crossover design, with a minimum 7-day washout in doses of each period.
  • Metoclopramide 10 mg

This multi-center trial will be conducted the United States. The overall time to participate in this study is approximately 8 weeks. Participants will make a final visit to the clinic 10-14 days after receiving their last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible for participation in this trial, the participant must:

  1. Has a documented diagnosis of diabetes mellitus gastroparesis (DG) or idiopathic gastroparesis (IG).
  2. Has a (BMI) greater than or equal to (>=) 18 and less than or equal to (\<=) 40 kilogram per square meter (kg/m\^2) at the Screening Visit.
  3. Be a non-smoker who has not used tobacco or nicotine-containing products (example, nicotine patch) for at least 6 months prior to trial drug administration of the initial dose of trial drug/invasive procedure.
  4. Has symptoms for gastroparesis (GP) (that is, chronic postprandial fullness, abdominal pain, postprandial nausea, vomiting, loss of appetite and/or early satiety) the past 3 months.
  5. Has documented slow gastric emptying (GE), with delayed GE by 13C-Spirulina gastric emptying breath test (GEBT) at Screening defined as >=80th percentile. Note: If a participant has had a documented scintigraphy or GEBT within the last 12 months that confirms the diagnosis of delayed GE, a screening GEBT would not be required.
  6. Has nausea subscale (of American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary [ANMS-GCSI-DD]) symptom score >=2 at least 3 of 7 days during Screening.
  7. Has (HBA1c) less than (\<) 10 percent (%) (for diabetes mellitus only).

Exclusion criteria

Exclusion Criteria

The participant must be excluded from participating in the trial if the participant:

  1. Has acute severe gastroenteritis and pronounced dehydration in the past 48 hours prior to Screening, gastric pacemaker, chronic parenteral feeding or persistent severe vomiting.
  2. Has a known disturbance of small intestinal absorption, exocrine pancreatic function, liver metabolism, and pulmonary function.
  3. Has a history of anorexia nervosa or bulimia.
  4. Previous history of bezoars (the presence of retained liquid, bile, or small amounts of poorly organized food residue is permitted).
  5. Difficulty swallowing solid food or pills.
  6. Prior surgery involving the luminal gastrointestinal (GI) tract (cholecystectomy, appendectomy, and hysterectomy are permitted if performed greater than (>) 3 months prior to SmartPill test).
  7. Any abdominal or pelvic surgery within the past 3 months.
  8. Known or history of inflammatory bowel disease.
  9. Has active diverticulitis, diverticular stricture, and other intestinal strictures.
  10. Had major surgery, donated or lost 1 unit of blood (approximately 500 milliliter [mL]) within 4 weeks prior to the pretrial (screening) visit milligram per deciliter (mg/dL) (14.99 millimole per liter [mmol/L]) during any visit up to and including the randomization visit (Period 1 Day 1 predose). Note: If the participant meets this exclusion criterion and the investigator believes that the value is not consistent with the participant's current self-monitoring blood glucose values, the participant should not be excluded at this time. The visit can be repeated within 5 to 7 days.
  11. Has had diabetic ketoacidosis (within the prior 4 weeks).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo

    TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.

    Drug: TAK-906 Maleate Placebo

  • Experimental
    Part 1: TAK 906 Maleate 5 mg

    TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.

    Drug: TAK-906 Maleate

  • Experimental
    Part 1: TAK 906 Maleate 25 mg

    TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.

    Drug: TAK-906 Maleate

  • Experimental
    Part 1: TAK 906 Maleate 100 mg

    TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.

    Drug: TAK-906 Maleate

  • Experimental
    Part 2: TAK-906 Maleate 25 mg Fed Condition

    TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.

    Drug: TAK-906 Maleate

  • Experimental
    Part 2: TAK-906 Maleate 25 mg Fasted Condition

    TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.

    Drug: TAK-906 Maleate

  • Active comparator
    Part 2: Metoclopramide 10 mg

    Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.

    Drug: Metaclopramide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any following reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.

    Time frame: From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)

  2. Number of Participants With Markedly Abnormal Laboratory Parameters Values

    Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,erythrocytes\<0.8 (10\^12/L)\*LLN, \>1.2(10\^12/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L). Participants with at least 1 markedly abnormal laboratory parameter value is reported.

    Time frame: From Baseline to 14 days after the last dose of study drug in Part 1 (Up to approximately 23 days)

  3. Number of Participants With Markedly Abnormal Vital Signs

    Vital signs included body temperature, diastolic and systolic blood pressure (mmHg), and heart rate (beats per minute \[bpm\]). Heart rate\<50 bpm and systolic blood pressure \<85 mmHg were considered markedly abnormal.

    Time frame: From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)

  4. Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values

    The 12-lead electrocardiogram (ECG) values outside the range Heart Rate \<50 (beats/min), PR Interval ≤120 (msec), PR Interval ≥200 (msec), QRS Duration ≥120 (msec), QT Interval ≥460 (msec) were considered markedly abnormal.

    Time frame: From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)

Secondary outcomes

  1. Change From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 1

    Change in serum prolactin on Day 1 at the Tmax, time of first occurrence of maximum serum concentration (Cmax) relative to Baseline was calculated as a ratio of maximum serum prolactin concentration on Day 1 to serum prolactin concentration at Baseline.

    Time frame: Day 1 predose (Baseline), 1 hour and at multiple timepoints (Up to 8 hours) postdose

  2. Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time as Measured by the 13C Spirulina GEBT Following Multiple Dose Administration of TAK-906 Maleate on Day 7 for Part 1

    The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.

    Time frame: Baseline and Day 7

  3. Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time Following Single Dose Administration of TAK-906 Maleate as Measured by the 13C Spirulina GEBT on Day 1

    The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.

    Time frame: Baseline and Day 1 of Part 1

  4. Percent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1

    SmartPill is an ingestible capsule that measures pressure, potential of hydrogen (pH) and temperature as it travels through the gastrointestinal (GI) tract to assess GE and GI motility. SmartPill eliminates radiation exposure and is the only motility test that provides a complete transit profile of the GI tract.

    Time frame: Baseline and Day 7

  5. AUCτ: Area Under the Plasma Concentration-time Curve From 0 to Time (T) Over the Dosing Interval for TAK-906 in Part 1

    Time frame: Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose

  6. Cmax: Maximum Observed Plasma Concentration for TAK 906 in Part 1

    Time frame: Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose

  7. Ctrough: Observed Concentration at the End of a Dosing Interval for TAK-906 in Part 1

    Time frame: Part 1: Predose on Days 2, 3, 4, 5, 6, 7, 8 and 9

  8. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1

    Time frame: Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose

07

Results

Posted Jul 23, 2019

Participant flow

Participants took part in the study at 7 investigative sites in the United States from 26 September 2017 to 09 March 2018.

Part 1 (Days 1 to 9)
Participant flow — Part 1 (Days 1 to 9)
MilestonePart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Under Fed ConditionsPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Started12141213000
Completed11141211000
Not completed1002000
Withdrew: Withdrawal by subject0001000
Withdrew: Adverse event0001000
Withdrew: Protocol deviation1000000
Part 2: Days 17 to 25
Participant flow — Part 2: Days 17 to 25
MilestonePart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Under Fed ConditionsPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Started00006015
Treated00006013
Completed00006013
Not completed0000002
Withdrew: Reason not specified0000001
Withdrew: Withdrawal by subject0000001
Part 2: Period 2: Fasted (Day 25)
Participant flow — Part 2: Period 2: Fasted (Day 25)
MilestonePart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Under Fed ConditionsPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Started0000060
Completed0000060
Not completed0000000

Outcome measures

PrimaryNumber of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any following reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.

Time frame:
From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Fed ConditionPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
TEAEs4434101
SAEs1001000
PrimaryNumber of Participants With Markedly Abnormal Laboratory Parameters Values

Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,erythrocytes\<0.8 (10\^12/L)\*LLN, \>1.2(10\^12/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L). Participants with at least 1 markedly abnormal laboratory parameter value is reported.

Time frame:
From Baseline to 14 days after the last dose of study drug in Part 1 (Up to approximately 23 days)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Laboratory Parameters Values
ParticipantsPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Hematocrit (%)<0.8 x LLN0100
Hemoglobin (g/L) <0.8 x LLN1000
ALT >3.0 U/Lx ULN0010
AST >3.0 U/L x ULN0010
BUN >10.7 mmol/L1001
Calcium >2.88 mmol/L0001
GGT >3 x ULN0001
Sodium (mmol/L) <130 mmol/L1000
PrimaryNumber of Participants With Markedly Abnormal Vital Signs

Vital signs included body temperature, diastolic and systolic blood pressure (mmHg), and heart rate (beats per minute \[bpm\]). Heart rate\<50 bpm and systolic blood pressure \<85 mmHg were considered markedly abnormal.

Time frame:
From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Vital Signs
ParticipantsPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Fed ConditionPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Heart Rate (bpm) <500100000
Systolic Blood Pressure (mmHg) <851000000
PrimaryNumber of Participants With Markedly Abnormal Electrocardiogram (ECG) Values

The 12-lead electrocardiogram (ECG) values outside the range Heart Rate \<50 (beats/min), PR Interval ≤120 (msec), PR Interval ≥200 (msec), QRS Duration ≥120 (msec), QT Interval ≥460 (msec) were considered markedly abnormal.

Time frame:
From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values
ParticipantsPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Fed ConditionPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Heart Rate (bpm) <501100110
PR Interval (msec) ≤1200111001
PR Interval (msec) ≥2001214004
QRS Duration (msec) ≥1200020000
QT Interval (msec) ≥4600101000
SecondaryChange From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 1

Change in serum prolactin on Day 1 at the Tmax, time of first occurrence of maximum serum concentration (Cmax) relative to Baseline was calculated as a ratio of maximum serum prolactin concentration on Day 1 to serum prolactin concentration at Baseline.

Time frame:
Day 1 predose (Baseline), 1 hour and at multiple timepoints (Up to 8 hours) postdose
Reported as:
Mean · ratio
Change From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 1
ratioPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Change From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 11.54 ± 0.70412.77 ± 9.10219.92 ± 13.60420.07 ± 9.170
Statistical analysis
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 5 mg · ANCOVA · p = <0.001 (ANCOVA model was used for analysis. Treatment, underlying disease (DG/IG) were fixed factors. ln of baseline prolactin concentration as covariate, ln of ratio of Cmax to baseline concentration as response. Results in original scale are presented.) · Least square (ls) mean difference: 7.38 · 95% CI 4.03 to 13.52
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 25 mg · ANCOVA · p = <0.001 (ANCOVA model was used for analysis. Treatment, underlying disease (DG/IG) were fixed factors. ln of baseline prolactin concentration as covariate, ln of ratio of Cmax to baseline concentration as response. Results in original scale are presented.) · Ls mean difference: 11.24 · 95% CI 5.91 to 21.41
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 100 mg · ANCOVA · p = <0.001 (ANCOVA model was used for analysis. Treatment, underlying disease (DG/IG) were fixed factors. ln of baseline prolactin concentration - covariate, ln of ratio of Cmax to baseline concentration as response. Results in original scale are presented.) · Ls mean difference: 12.80 · 95% CI 6.94 to 23.59
SecondaryChange From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time as Measured by the 13C Spirulina GEBT Following Multiple Dose Administration of TAK-906 Maleate on Day 7 for Part 1

The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.

Time frame:
Baseline and Day 7
Reported as:
Mean · min
Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time as Measured by the 13C Spirulina GEBT Following Multiple Dose Administration of TAK-906 Maleate on Day 7 for Part 1
minPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Baseline118.74 ± 43.106130.18 ± 35.316121.26 ± 33.606122.50 ± 31.803
Change from Baseline at Day 74.55 ± 16.3326.21 ± 36.9867.80 ± 52.9467.72 ± 24.609
Statistical analysis
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 5 mg · ANCOVA · p = 0.599 (P-value was obtained by ANCOVA model with treatment and underlying disease (DG/IG) condition as fixed factors and baseline score as covariate.) · Ls mean difference: 7.76 · 95% CI -21.89 to 37.41
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 25 mg · ANCOVA · p = 0.687 (P-value was obtained by ANCOVA model with treatment and underlying disease (DG/IG) condition as fixed factors and baseline score as covariate.) · Ls mean difference: 6.28 · 95% CI -25.04 to 37.59
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 100 mg · ANCOVA · p = 0.605 (P-value was obtained by ANCOVA model with treatment and underlying disease (DG/IG) condition as fixed factors and baseline score as covariate.) · Ls mean difference: 8.05 · 95% CI -23.22 to 39.33
SecondaryChange From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time Following Single Dose Administration of TAK-906 Maleate as Measured by the 13C Spirulina GEBT on Day 1

The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.

Time frame:
Baseline and Day 1 of Part 1
Reported as:
Mean · minute (min)
Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time Following Single Dose Administration of TAK-906 Maleate as Measured by the 13C Spirulina GEBT on Day 1
minute (min)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Baseline118.74 ± 43.106130.18 ± 35.316121.26 ± 33.606122.50 ± 31.803
Change from Baseline at Day 1-5.71 ± 21.6870.12 ± 21.7366.74 ± 44.3900.71 ± 21.192
Statistical analysis
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 5 mg · ANCOVA · p = 0.522 (P-value was obtained by ANCOVA model with treatment and underlying disease (DG/IG) condition as fixed factors and baseline score as covariate.) · Ls mean difference: 7.56 · 95% CI -16.06 to 31.19
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 25 mg · ANCOVA · p = 0.293 (P-value was obtained by ANCOVA model with treatment and underlying disease (DG/IG) condition as fixed factors and baseline score as covariate.) · Ls mean difference: 12.92 · 95% CI -11.58 to 37.43
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 100 mg · ANCOVA · p = 0.551 (P-value was obtained by ANCOVA model with treatment and underlying disease (DG/IG) condition as fixed factors and baseline score as covariate.) · Ls mean difference: 7.00 · 95% CI -16.52 to 30.52
SecondaryPercent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1

SmartPill is an ingestible capsule that measures pressure, potential of hydrogen (pH) and temperature as it travels through the gastrointestinal (GI) tract to assess GE and GI motility. SmartPill eliminates radiation exposure and is the only motility test that provides a complete transit profile of the GI tract.

Time frame:
Baseline and Day 7
Reported as:
Mean · percent change in GE time
Percent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1
percent change in GE timePart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Percent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1124.62 ± 181.12561.72 ± 195.867419.27 ± 885.36271.09 ± 121.584
Statistical analysis
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 5 mg · Wilcoxon Rank Sum tests · p = 0.274 (P-value was obtained with pairwise Wilcoxon Rank Sum tests.) · Hodges-lehmann estimate of median diff: -18.14 · 95% CI -307.58 to 13.56
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 25 mg · Wilcoxon Rank Sum tests · p = 0.481 (P-value was obtained with pairwise Wilcoxon Rank Sum tests.) · Hodges-lehmann estimate of median diff: -26.95 · 95% CI -229.73 to 530.49
  • Part 1: Placebo vs Part 1: TAK 906 Maleate 100 mg · Wilcoxon Rank Sum tests · p = 0.382 (P-value was obtained with pairwise Wilcoxon Rank Sum tests.) · Hodges-lehmann estimate of median diff: -24.49 · 95% CI -225.87 to 98.91
SecondaryAUCτ: Area Under the Plasma Concentration-time Curve From 0 to Time (T) Over the Dosing Interval for TAK-906 in Part 1
Time frame:
Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Mean · h*ng/mL
AUCτ: Area Under the Plasma Concentration-time Curve From 0 to Time (T) Over the Dosing Interval for TAK-906 in Part 1
h*ng/mLPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Day 14.67 ± 1.6923.0 ± 7.76131 ± 44.8
Day 75.46 ± 2.0726.3 ± 11.3166 ± 93.0
SecondaryCmax: Maximum Observed Plasma Concentration for TAK 906 in Part 1
Time frame:
Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for TAK 906 in Part 1
ng/mLPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Day 12.27 ± 0.81912.0 ± 5.3675.7 ± 39.9
Day 72.87 ± 1.7815.5 ± 5.5899.6 ± 69.4
SecondaryCtrough: Observed Concentration at the End of a Dosing Interval for TAK-906 in Part 1
Time frame:
Part 1: Predose on Days 2, 3, 4, 5, 6, 7, 8 and 9
Reported as:
Mean · ng/mL
Ctrough: Observed Concentration at the End of a Dosing Interval for TAK-906 in Part 1
ng/mLPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Predose on Day 20.0121 ± 0.03150.262 ± 0.3490.770 ± 0.513
Predose on Day 30.0423 ± 0.05270.503 ± 0.6400.958 ± 0.750
Predose on Day 40.0178 ± 0.05030.302 ± 0.2141.17 ± 0.799
Predose on Day 50.0457 ± 0.09621.09 ± 1.971.95 ± 2.38
Predose on Day 60.0423 ± 0.05020.412 ± 0.4151.01 ± 0.469
Predose on Day 70.0596 ± 0.09050.336 ± 0.3831.48 ± 0.936
Predose on Day 80.0763 ± 0.1000.522 ± 0.6481.16 ± 0.878
Predose on Day 90.0700 ± 0.1200.280 ± 0.2431.40 ± 1.08
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1
Time frame:
Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose
Reported as:
Median · hour (hr)
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1
hour (hr)Part 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mg
Day 11.00 (0.48 to 2.00)1.00 (0.50 to 4.00)1.00 (0.50 to 2.00)
Day 71.00 (0.50 to 2.00)1.00 (0.50 to 1.52)0.98 (0.48 to 1.98)

Adverse events

Collected over Baseline to 14 days after the last dose of study drug (Up to approximately 39 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/12 (0%)1/12 (8.3%)3/12 (25%)
Part 1: TAK 906 Maleate 5 mg0/14 (0%)0/14 (0%)4/14 (28.6%)
Part 1: TAK 906 Maleate 25 mg0/12 (0%)0/12 (0%)3/12 (25%)
Part 1: TAK 906 Maleate 100 mg0/13 (0%)1/13 (7.7%)4/13 (30.8%)
Part 2: TAK-906 Maleate 25 mg Fed Condition0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 2: TAK-906 Maleate 25 mg Fasted Condition0/6 (0%)0/6 (0%)0/6 (0%)
Part 2: Metoclopramide 10 mg0/13 (0%)0/13 (0%)1/13 (7.7%)
Most frequent serious events
Most frequent serious events
EventPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Fed ConditionPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Acute kidney injuryRenal and urinary disorders1/120/140/121/130/60/60/13
Urinary tract infectionInfections and infestations0/120/140/121/130/60/60/13
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPart 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgPart 2: TAK-906 Maleate 25 mg Fed ConditionPart 2: TAK-906 Maleate 25 mg Fasted ConditionPart 2: Metoclopramide 10 mg
Urinary tract infectionInfections and infestations0/121/140/120/131/60/60/13
FatigueGeneral disorders0/122/140/120/130/60/60/13
PalpitationsCardiac disorders0/120/141/120/130/60/60/13
DiarrhoeaGastrointestinal disorders1/120/141/121/130/60/60/13
Abdominal painGastrointestinal disorders1/120/140/120/130/60/60/13
Abdominal pain upperGastrointestinal disorders1/120/140/120/130/60/60/13
ConjunctivitisInfections and infestations1/120/140/120/130/60/60/13
Liver function test increasedInvestigations0/120/141/121/130/60/60/13
HeadacheNervous system disorders1/120/141/121/130/60/60/13
Muscle spasmsMusculoskeletal and connective tissue disorders0/120/140/120/130/60/61/13

Baseline characteristics

Safety analysis set (SAS), Part 1, included all participants who were randomized (Part 1) and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Mean49.9 ± 13.8454.7 ± 11.7552.7 ± 17.1355.9 ± 10.1953.4 ± 13.14
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Female911101040
Male332311
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Hispanic or Latino953724
Non-Hispanic and Latino399627
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Black or African American11428
White111371142
Multiracial00101
Region of Enrollment
Region of Enrollment(Participants)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
United States1214121351
Height
Height(cm)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Mean164.62 ± 9.790163.95 ± 6.751164.56 ± 7.204164.93 ± 9.778164.50 ± 8.212
Weight
Weight(kg)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Mean74.70 ± 17.23179.86 ± 13.47080.55 ± 11.34688.24 ± 11.80380.95 ± 14.064
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Part 1: PlaceboPart 1: TAK 906 Maleate 5 mgPart 1: TAK 906 Maleate 25 mgPart 1: TAK 906 Maleate 100 mgTotal
Mean27.282 ± 4.227629.679 ± 4.504329.832 ± 4.546132.565 ± 4.400129.887 ± 4.6805

1 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • 9171 West Thunderbird Road
    Peoria, Arizona 85381, United States
  • 850 North Kolb Road
    Tucson, Arizona 85710, United States
  • 11219 Financial Centre Parkway
    Little Rock, Arkansas 72211, United States
  • 13055 Southwest 42nd Street
    Miami, Florida 33175, United States
  • 8200 Southwest 117th Avenue
    Miami, Florida 33183, United States
  • 125 Clairemont Avenue
    Decatur, Georgia 30030, United States
  • 616 South Washington Street
    Bastrop, Louisiana 71220, United States
  • 6035 Shallowford Road
    Chattanooga, Tennessee 37421, United States
  • 26 Stonecreek Circle
    Jackson, Tennessee 38305, United States
09

References and documents

Publications

  • Kuo B, Scimia C, Dukes G, Zhang W, Gupta S, Chen C, Chuang E, Camilleri M. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. Aliment Pharmacol Ther. 2021 Aug;54(3):267-280. doi: 10.1111/apt.16451. Epub 2021 Jun 20. PubMed 34148244 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Mar 2018, 5 months.

Results were first posted in Jul 2019, 1 year 4 months after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 5 months is below that.

Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2017
First posted
Aug 31, 2017
StartActual
Sep 26, 2017
Primary completionActual
Mar 9, 2018
CompletionActual
Mar 9, 2018
Results first posted
Jul 23, 2019
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03268941
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
Sep 26, 2017
Primary completion
Mar 9, 2018
Completion
Mar 9, 2018
Results posted
Jul 23, 2019
Last update
Jan 6, 2021

Study contacts

Study Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazpiroben

Start the discussion